Literature DB >> 9067928

Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications.

D C Cattran1, Y Pei, C M Greenwood, C Ponticelli, P Passerini, E Honkanen.   

Abstract

Although a number of factors have consistently correlated with progression to chronic renal insufficiency (CRI) in idiopathic membranous glomerulonephropathy (IMGN), they appear late, are not quantitative in nature and have not been validated. We have determined that the highest sustained six-month period of proteinuria is an important predictor of progression. Using multiple logistic modelling, the only additional prognostic variables of importance in 184 Canadian patients were the initial creatinine clearance and the rate of change in function over this six-month interval. Independent data from Italy (101 patients) and Finland (78 patients) were obtained for comparison. Sensitivity, specificity, negative and positive predictive values and overall accuracy, as well as Pearson's goodness-of-fit and Harrell's "C" statistic were used to assess the fits of the model. Accuracy of prediction was > or = 85% in all three countries. Pearson's Chi-square goodness-of-fit showed good agreement across the spectrum and Harrell's "C" statistic was > or = 90%. Therefore, a predictive, semiquantitative algorithm in IMGN has been validated. Its relevance in patient management and in clinical trials is illustrated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9067928     DOI: 10.1038/ki.1997.127

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  62 in total

1.  Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy.

Authors:  Jan A J G van den Brand; Peter R van Dijk; Julia M Hofstra; Jack F M Wetzels
Journal:  J Am Soc Nephrol       Date:  2013-09-12       Impact factor: 10.121

2.  Prognostic value of risk score and urinary markers in idiopathic membranous nephropathy.

Authors:  Jan A J G van den Brand; Julia M Hofstra; Jack F M Wetzels
Journal:  Clin J Am Soc Nephrol       Date:  2012-05-17       Impact factor: 8.237

3.  M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.

Authors:  Elion Hoxha; Sigrid Harendza; Hans Pinnschmidt; Ulf Panzer; Rolf A K Stahl
Journal:  Clin J Am Soc Nephrol       Date:  2014-09-29       Impact factor: 8.237

Review 4.  Treatment of membranous nephropathy: time for a paradigm shift.

Authors:  Piero Ruggenenti; Fernando C Fervenza; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2017-07-03       Impact factor: 28.314

5.  Glomerular disease: Predicting outcomes in idiopathic membranous nephropathy.

Authors:  Manuel Praga; Jorge Rojas-Rivera
Journal:  Nat Rev Nephrol       Date:  2012-07-17       Impact factor: 28.314

6.  Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy.

Authors:  Choli Hartono; Miriam Chung; Sheng F Kuo; Surya V Seshan; Thangamani Muthukumar
Journal:  J Nephrol       Date:  2014-01-16       Impact factor: 3.902

7.  Membranous Nephropathy: Quantifying Remission Duration on Outcome.

Authors:  Daniel C Cattran; Esther D Kim; Heather Reich; Michelle Hladunewich; S Joseph Kim
Journal:  J Am Soc Nephrol       Date:  2016-10-18       Impact factor: 10.121

8.  Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy.

Authors:  Howard A Austin; Gabor G Illei; Michelle J Braun; James E Balow
Journal:  J Am Soc Nephrol       Date:  2009-03-18       Impact factor: 10.121

9.  Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis.

Authors:  Sean J Barbour; Daniel C Cattran; Gabriela Espino-Hernandez; Michelle A Hladunewich; Heather N Reich
Journal:  Kidney Int       Date:  2015-08-19       Impact factor: 10.612

Review 10.  Membranous nephropathy in children: clinical presentation and therapeutic approach.

Authors:  Shina Menon; Rudolph P Valentini
Journal:  Pediatr Nephrol       Date:  2009-11-12       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.